CA-125 in Screening Patients at High Risk for Ovarian Cancer
This study is currently recruiting patients.
Sponsored by: |
UAB Comprehensive Cancer Center
|
Information provided by: |
National Cancer Institute (NCI) |
Purpose
RATIONALE: Measuring levels of CA 125 in blood samples of women who have a high risk of developing ovarian cancer may help
doctors detect cancer early and plan more effective treatment.
PURPOSE: Phase II trial to study the effectiveness of monitoring CA-125 levels in screening for cancer in women who are at
high risk of developing ovarian cancer.
Condition
|
Treatment or Intervention |
Phase |
ovarian epithelial cancer
|
Procedure: screening intervention Procedure: study of high risk factors Procedure: study of physiologic variables
|
Phase II
|
MedlinePlus related topics: Ovarian Cancer
Study Type: Observational
Study Design: Screening
Official Title: Phase II Pilot Study of CA 125 Screening in Patients at High Risk for Ovarian Cancer
Further Study Details:
OBJECTIVES: Primary
- Determine the feasibility of prospective screening for ovarian cancer in high-risk patients.
- Determine normal ranges and distributions of CA 125 within and between these patients (with subclassification by menopausal
status, estrogen replacement therapy usage, and prophylactic oophorectomy).
Secondary
- Determine estimates of the specificity and positive predictive value of a risk of cancer algorithm suitable for designing
a definitive trial of screening for ovarian cancer in these patients.
OUTLINE: This is a multicenter, pilot study.
Patients undergo blood collection and CA 125 levels are measured at baseline and then every 3 months for 1-2 years. Patients
may be referred for an ovarian ultrasound if indicated by the CA 125 results.
Patients are followed at 6 months and then annually thereafter.
PROJECTED ACCRUAL: A total of 2,400 patients will be accrued for this study within 1 year.
Eligibility
Ages Eligible for Study:
30 Years and above,
Genders Eligible for Study:
Both
DISEASE CHARACTERISTICS:
- At high risk for developing ovarian cancer, as determined by meeting criteria for 1 of the following:
- Family history of at least 2 ovarian or breast* cancers among the patient and first- and second-degree relatives within the
same lineage**
- If breast cancer* is required to meet this criterion, at least 1 breast cancer* must be premenopausal (diagnosed at age 50
or under if menopausal status unknown) NOTE: **Multiple primary cancers in the same person satisfies this criterion
- Ashkenazi Jewish ethnicity and meets criteria for 1 of the following:
- Prior breast cancer* diagnosis
- One first-degree or 2 second-degree relatives with breast* or ovarian cancer
- If breast cancer is required to meet this criterion, at least 1 breast cancer* must be premenopausal (diagnosed at age 50
or under if menopausal status unknown)
- Probability of BRCA1 or BRCA2 mutation greater than 20%, as determined by BRCAPRO 95% posterior probability interval
- This criterion includes the following situations for which BRCAPRO is not required:
- Tested positive for a BRCA1 or BRCA2 mutation (100% probability)
- First- or second-degree relative with a BRCA1 or BRCA2 mutation NOTE: *Including ductal carcinoma in situ
- No ovarian cancer, including low malignant potential cancers or primary papillary serous carcinoma of the peritoneum
PATIENT CHARACTERISTICS: Age
Performance status
Life expectancy
Hematopoietic
- No hemophilia
- No other bleeding disorders
Hepatic
Renal
Pulmonary
Other
- Not pregnant
- Negative pregnancy test
- Fertile patients must use effective contraception
- No psychiatric or psychological condition that would preclude giving informed consent
- No concurrent untreated malignancy except nonmelanoma skin cancer
- No other medical condition that would preclude blood draws (e.g., chronic infectious disease)
PRIOR CONCURRENT THERAPY: Biologic therapy
Chemotherapy
- More than 3 months since prior adjuvant chemotherapy for cancer
Endocrine therapy
- Concurrent adjuvant hormonal therapy (e.g., tamoxifen, leuprolide, or goserelin) allowed
Radiotherapy
- More than 3 months since prior adjuvant radiotherapy for cancer
Surgery
- More than 3 months since prior intraperitoneal surgery (laparoscopy or laparotomy)
- Prior prophylactic oophorectomy allowed
Other
- More than 5 years since prior treatment (excluding hormonal therapy) for metastatic malignancy
- No concurrent participation in other ovarian cancer early detection trials
Location
and Contact
Information
Alabama University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham,
Alabama,
35294-3300,
United States; Recruiting
Edward E. Partridge, MD
205-934-4986
Study chairs or principal investigators
Edward E. Partridge, MD, Principal Investigator, UAB Comprehensive Cancer Center
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Study ID Numbers:
CDR0000353332; UAB-120; UAB-0120
Record last reviewed:
March 2004
Record first received:
April 7, 2004
ClinicalTrials.gov Identifier:
NCT00080639Health Authority: Unspecified
ClinicalTrials.gov processed this record on 2004-11-05